Literature DB >> 20678514

Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.

Matthew L Banks1, John E Folk, Kenner C Rice, S Stevens Negus.   

Abstract

Mu-opioid receptor agonists such as fentanyl are effective analgesics, but their clinical use is limited by untoward effects. Adjunct medications may improve the effectiveness and/or safety of opioid analgesics. This study compared interactions between fentanyl and either the noncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine or the delta-opioid receptor agonist SNC162 [(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-phenyl)methyl]-N,N-diethylbenzamide] in two behavioral assays in rhesus monkeys. An assay of thermal nociception evaluated tail-withdrawal latencies from water heated to 50 and 54°C. An assay of schedule-controlled responding evaluated response rates maintained under a fixed-ratio 30 schedule of food presentation. Effects of each drug alone and of three mixtures of ketamine+fentanyl (22:1, 65:1, 195:1 ketamine/fentanyl) or SNC162+fentanyl (59:1, 176:1, 528:1 SNC162/fentanyl) were evaluated in each assay. All drugs and mixtures dose-dependently decreased rates of food-maintained responding, and drug proportions in the mixtures were based on relative potencies in this assay. Ketamine and SNC162 were inactive in the assay of thermal antinociception, but fentanyl and all mixtures produced dose-dependent antinociception. Drug interactions were evaluated using dose-addition and dose-ratio analysis. Dose-addition analysis revealed that interactions for all ketamine/fentanyl mixtures were additive in both assays. SNC162/fentanyl interactions were usually additive, but one mixture (176:1) produced synergistic antinociception at 50°C. Dose-ratio analysis indicated that ketamine failed to improve the relative potency of fentanyl to produce antinociception vs. rate suppression, whereas two SNC162/fentanyl mixtures (59:1 and 176:1) increased the relative potency of fentanyl to produce antinociception. These results suggest that delta agonists may produce more selective enhancement than ketamine of mu agonist-induced antinociception.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20678514      PMCID: PMC2967222          DOI: 10.1016/j.pbb.2010.07.019

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  42 in total

1.  Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice.

Authors:  S J O'Neill; M A Collins; H O Pettit; R W McNutt; K J Chang
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

Review 2.  N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics.

Authors:  Dean G Brown; Johannes J Krupp
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

3.  Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys.

Authors:  S S Negus; M B Gatch; N K Mello; X Zhang; K Rice
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

4.  Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.

Authors:  J S Heyman; S A Mulvaney; H I Mosberg; F Porreca
Journal:  Brain Res       Date:  1987-09-08       Impact factor: 3.252

5.  Interactions between delta and mu opioid agonists in assays of schedule-controlled responding, thermal nociception, drug self-administration, and drug versus food choice in rhesus monkeys: studies with SNC80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and heroin.

Authors:  Glenn W Stevenson; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2005-03-25       Impact factor: 4.030

Review 6.  Transmitters involved in antinociception in the spinal cord.

Authors:  S Fürst
Journal:  Brain Res Bull       Date:  1999-01-15       Impact factor: 4.077

7.  Analgesic effects of phencyclidine-like drugs in rhesus monkeys.

Authors:  C P France; A M Snyder; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1989-07       Impact factor: 4.030

8.  A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys.

Authors:  L A Dykstra; J H Woods
Journal:  J Pharmacol Methods       Date:  1986-06

9.  Subanaesthetic ketamine spares postoperative morphine and controls pain better than standard morphine does alone in orthopaedic-oncological patients.

Authors:  Yehuda Kollender; Jacob Bickels; Daniel Stocki; Nissim Maruoani; Shoshana Chazan; Alexander Nirkin; Isaac Meller; Avi A Weinbroum
Journal:  Eur J Cancer       Date:  2008-04-07       Impact factor: 9.162

10.  Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain[ISRCTN83088383].

Authors:  Adam P Tucker; Yong Ik Kim; Raymond Nadeson; Colin S Goodchild
Journal:  BMC Anesthesiol       Date:  2005-04-02       Impact factor: 2.217

View more
  9 in total

1.  Nicotine Enhances the Hypnotic and Hypothermic Effects of Alcohol in the Mouse.

Authors:  Cassandra A Slater; Asti Jackson; Pretal P Muldoon; Anton Dawson; Megan O'Brien; Lindsey G Soll; Rehab Abdullah; F Ivy Carroll; Andrew R Tapper; Michael F Miles; Matthew L Banks; Jill C Bettinger; Imad M Damaj
Journal:  Alcohol Clin Exp Res       Date:  2016-01       Impact factor: 3.455

2.  Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.

Authors:  Kathryn L Schwienteck; S Stevens Negus; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2019-06       Impact factor: 2.293

3.  Vaccine blunts fentanyl potency in male rhesus monkeys.

Authors:  Rebekah D Tenney; Steven Blake; Paul T Bremer; Bin Zhou; Candy S Hwang; Justin L Poklis; Kim D Janda; Matthew L Banks
Journal:  Neuropharmacology       Date:  2019-07-29       Impact factor: 5.250

4.  Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy.

Authors:  Matthew L Banks; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2010-07-30       Impact factor: 4.030

5.  Additive and subadditive antiallodynic interactions between μ-opioid agonists and N-methyl D-aspartate antagonists in male rhesus monkeys.

Authors:  Jeremy C Cornelissen; Floyd F Steele; Kenner C Rice; Katherine L Nicholson; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

6.  Effects of the delta-opioid agonist SNC80 on the abuse liability of methadone in rhesus monkeys: a behavioral economic analysis.

Authors:  Matthew L Banks; Peter G Roma; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2011-03-03       Impact factor: 4.530

7.  Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.

Authors:  Jeremy C Cornelissen; Samuel Obeng; Kenner C Rice; Yan Zhang; S Stevens Negus; Matthew L Banks
Journal:  J Pharmacol Exp Ther       Date:  2018-01-12       Impact factor: 4.030

8.  Development of a Clinically Viable Heroin Vaccine.

Authors:  Paul T Bremer; Joel E Schlosburg; Matthew L Banks; Floyd F Steele; Bin Zhou; Justin L Poklis; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-06-20       Impact factor: 15.419

9.  Interaction between Mu and Delta Opioid Receptor Agonists in an Assay of Capsaicin-Induced Thermal Allodynia in Rhesus Monkeys.

Authors:  S Stevens Negus; Ember M Morrissey; John E Folk; Kenner C Rice
Journal:  Pain Res Treat       Date:  2012-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.